RBC Capital Initiates Coverage on Rigel Pharmaceuticals (RIGL) with an Outperform
More News related to RIGL
- Rigel Pharma (RIGL) volatility elevated into topline results
- Rigel to Present at Jefferies Healthcare Conference
- Rodman & Renshaw Starts Rigel Pharma (RIGL) at Market Outperform, Multi-Billion Drug Potential
- Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers
- Barclays Gets Bullish On US Biotechnology Sector (BBH)
RBC Capital initiates coverage on Rigel Pharmaceuticals (Nasdaq: RIGL) with an Outperform. Price target $31.
Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company that discovers and develops small molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer and viral diseases.
Related Categories
New CoverageStocks Mentioned
-0.37Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
